FAKTOR-ZERTIFIKAT - VERTEX PHARMACEUTICALS | Real-time Bid/Ask 10:05:16 27/06/2024 BST | ||
| 1.63 EUR / 1.68 EUR | +0.30% |
|
| Current month | -12.23% | ||
| 1 month | -11.76% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 27/06/24 | 1.63 | -1.21% |
| 26/06/24 | 1.65 | 0.00% |
| 25/06/24 | 1.65 | +1.85% |
| 24/06/24 | 1.62 | -4.14% |
| 21/06/24 | 1.69 | +0.60% |
Delayed Quote Börse Stuttgart
Last update June 27, 2024 at 09:45 am
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | J.P. Morgan |
| WKN | JK2J1W |
| ISIN | DE000JK2J1W5 |
| Date issued | 23/02/2024 |
| Strike | 632 $ |
| Maturity | Unlimited |
| Parity | 91.73 : 1 |
| Emission price | 2.52 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 3.15 € |
|---|---|
| Lowest since issue | 1.51 € |
| Spread | 0.05 € |
| Spread % | 2.98% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
474
USD
Average target price
465.5
USD
Spread / Average Target
-1.79%
- Stock Market
- Certificates
- Certificat
